CSC
CNTA

Caldwell Sutter Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Caldwell Sutter Capital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-43
Closed -$618 – 867
2025
Q1 		$618 Hold
43
– – ﹤0.01% 821
2024
Q4 		$720 Sell
43
-43
-50% -$712 ﹤0.01% 833
2024
Q3 		$1.38K Hold
86
– – ﹤0.01% 794
2024
Q2 		$777 Hold
86
– – ﹤0.01% 839
2024
Q1 		$972 Sell
86
-86
-50% -$814 ﹤0.01% 824
2023
Q4 		$1.37K Buy
+172
New +$1.15K ﹤0.01% 795

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caldwell Sutter Capital's CNTA Position: Q2 2025 in Review

Caldwell Sutter Capital sold out of Centessa Pharmaceuticals (CNTA) in Q2 2025, closing a stake of 43 shares — an estimated $618 sold.

Caldwell Sutter Capital first reported a position in CNTA in Q4 2023 and held it in 6 quarters. The position peaked at $1.38K in Q3 2024. 117 funds tracked by Wall St. Rank hold CNTA as of Q2 2025.

  • Caldwell Sutter Capital reported no remaining Centessa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Caldwell Sutter Capital sold 43 Centessa Pharmaceuticals shares in Q2 2025, an estimated $618.
  • Caldwell Sutter Capital first reported a position in Centessa Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • Caldwell Sutter Capital's Centessa Pharmaceuticals position peaked at $1.38K in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2025.

Based on Caldwell Sutter Capital's 13F filing for Q2 2025, filed 11 Jul 2025.